Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27098253 | 0.73 | TSHR (0.42) | ADRB2HTR1ALMNACYP1A2SMN1; SMN2 | |
| SCHEMBL2830568 | 0.73 | MTNR1A (0.67) | LMNADRD2KMT2AHSD17B10MTNR1A | |
| SCHEMBL3514820 | 0.72 | MTNR1A (0.61) | LMNASMN1; SMN2DRD2KMT2AHSD17B10 | |
| SCHEMBL1643653 | 0.68 | MEN1 (0.45) | ADRB2HTR1ACKS1BSKP1SKP2 | |
| SCHEMBL15189256 | 0.68 | NPC1 (0.52) | LMNASMN1; SMN2CKS1BSKP1SKP2 | |
| SCHEMBL25496763 | 0.67 | DRD2 (0.56) | DRD2MEN1KMT2A | |
| SCHEMBL22137526 | 0.67 | TDP1 (0.43) | CKS1BSKP1SKP2MEN1KMT2A | |
| SCHEMBL19423125 | 0.67 | EPHX2 (0.56) | LMNAKDM4ESMN1; SMN2DRD2MEN1 | |
| Oxalic Acid SCHEMBL7276233 | 0.67 | LMNA (0.51) | HTR1ALMNACYP1A2KDM4ESMN1; SMN2 | |
| SCHEMBL8401489 | 0.67 | AKT1 (0.47) | CKS1BSKP1SKP2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677336-B2 | PARTIAL FATTY ACID OXIDATION INHIBITORS; PROTECT SKELETAL MUSCLES AGAINST DAMAGE RESULTING FROM TRAUMA OR SYSTEMIC DISEASES, TREAT SHOCK CONDITIONS, PRESERVE DONOR TISSUE AND ORGANS USED IN TRANSPLANTS | CV THERAPEUTICS, INC. | 2004-01-13 | — | — | US | disclosed |
| EP-1259493-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020016463-A1 | Substituted piperazine compounds | CV THERAPEUTICS, INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001062744-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016463-A1 | Substituted piperazine compounds | ATP2A1, CPT1B, TNNC1 | ADRB2 135/4885HTR1A 4573/4885LMNA 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.